[{"AccountsPayableCurrent_0_Q3_USD":2599000.0,"OtherNonoperatingIncomeExpense_1_Q3_USD":105000.0,"OtherAccruedLiabilitiesNoncurrent_0_Q3_USD":35000.0,"OtherAccruedLiabilitiesCurrent_0_Q3_USD":303000.0,"OperatingIncomeLoss_3_Q3_USD":-33335000.0,"OperatingIncomeLoss_1_Q3_USD":-9981000.0,"OperatingExpenses_3_Q3_USD":33335000.0,"OperatingExpenses_1_Q3_USD":9981000.0,"NonoperatingIncomeExpense_3_Q3_USD":19000.0,"NonoperatingIncomeExpense_1_Q3_USD":117000.0,"NetIncomeLoss_3_Q3_USD":-34598000.0,"NetIncomeLoss_1_Q3_USD":-10196000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-35647000.0,"NetCashProvidedByUsedInInvestingActivities_3_Q3_USD":-2196000.0,"NetCashProvidedByUsedInFinancingActivities_3_Q3_USD":84588000.0,"LiabilitiesCurrent_0_Q3_USD":7344000.0,"LiabilitiesAndStockholdersEquity_0_Q3_USD":193865000.0,"Liabilities_0_Q3_USD":7379000.0,"OtherNonoperatingIncomeExpense_3_Q3_USD":-13000.0,"InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_0_Q3_USD":1028000.0,"PaymentsOfStockIssuanceCosts_3_Q3_USD":1612000.0,"PaymentsToAcquireInterestInJointVenture_3_Q3_USD":2000000.0,"StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0_Q3_USD":186486000.0,"StockholdersEquity_0_Q3_USD":186486000.0,"ShareBasedCompensation_3_Q3_USD":2116000.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":-81612000.0,"ResearchAndDevelopmentExpense_3_Q3_USD":20815000.0,"ResearchAndDevelopmentExpense_1_Q3_USD":4960000.0,"PropertyPlantAndEquipmentNet_0_Q3_USD":445000.0,"ProfitLoss_3_Q3_USD":-34598000.0,"ProceedsFromIssuanceOfCommonStock_3_Q3_USD":0.0,"ProceedsFromIssuanceInitialPublicOffering_3_Q3_USD":86200000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q3_USD":5414000.0,"PreferredStockValue_0_Q3_USD":null,"PreferredStockSharesOutstanding_0_Q3_shares":0.0,"PreferredStockSharesIssued_0_Q3_shares":0.0,"PreferredStockSharesAuthorized_0_Q3_shares":50000000.0,"PreferredStockParOrStatedValuePerShare_0_Q3_USD":0.0001,"PaymentsToAcquirePropertyPlantAndEquipment_3_Q3_USD":196000.0,"PaymentsToAcquireEquityMethodInvestments_3_Q3_USD":2000000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q3_shares":27527770.0,"InterestExpense_3_Q3_USD":10000.0,"InterestAndOtherIncome_3_Q3_USD":42000.0,"CommonStockSharesAuthorized_0_Q3_shares":200000000.0,"CommonStockParOrStatedValuePerShare_0_Q3_USD":0.0001,"CommitmentsAndContingencies_0_Q3_USD":null,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_3_Q3_USD":46745000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q3_USD":186978000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q3_USD":186978000.0,"CapitalExpendituresIncurredButNotYetPaid_3_Q3_USD":36000.0,"AssetsCurrent_0_Q3_USD":192392000.0,"Assets_0_Q3_USD":193865000.0,"AllocatedShareBasedCompensationExpense_3_Q3_USD":2116000.0,"AllocatedShareBasedCompensationExpense_1_Q3_USD":1055000.0,"AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_3_Q3_USD":2116000.0,"AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_1_Q3_USD":1055000.0,"AdditionalPaidInCapital_0_Q3_USD":268095000.0,"AccruedProfessionalFeesCurrent_0_Q3_USD":364000.0,"AccruedLiabilitiesCurrent_0_Q3_USD":4745000.0,"AccruedEmployeeBenefitsCurrent_0_Q3_USD":2097000.0,"CommonStockSharesIssued_0_Q3_shares":32129970.0,"InterestExpense_1_Q3_USD":0.0,"CommonStockSharesOutstanding_0_Q3_shares":32129970.0,"ComprehensiveIncomeNetOfTax_1_Q3_USD":-10196000.0,"InterestAndOtherIncome_1_Q3_USD":12000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3_Q3_USD":4386000.0,"IncreaseDecreaseInAccruedLiabilities_3_Q3_USD":472000.0,"IncreaseDecreaseInAccountsPayable_3_Q3_USD":-607000.0,"IncomeTaxExpenseBenefit_3_Q3_USD":0.0,"IncomeTaxExpenseBenefit_1_Q3_USD":0.0,"IncomeLossFromEquityMethodInvestments_3_Q3_USD":-1282000.0,"IncomeLossFromEquityMethodInvestments_1_Q3_USD":-332000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3_Q3_USD":-33316000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q3_USD":-9864000.0,"GeneralAndAdministrativeExpense_3_Q3_USD":12520000.0,"GeneralAndAdministrativeExpense_1_Q3_USD":5021000.0,"EarningsPerShareBasicAndDiluted_3_Q3_USD":-1.44,"EarningsPerShareBasicAndDiluted_1_Q3_USD":-0.37,"DepreciationAndAmortization_3_Q3_USD":74000.0,"DeferredOfferingCosts_0_Q3_USD":0.0,"ComprehensiveIncomeNetOfTax_3_Q3_USD":-34598000.0,"CommonStockValue_0_Q3_USD":3000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3_Q3_shares":24011862.0,"Ticker":"RLYB","CIK":"1739410","name":"RALLYBIO CORP","OfficialName":"Rallybio Corporation Common Stock","form":"10-Q","period":"20210930","fy":"2021.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"312955648.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20211110"}]